PCRX
NASDAQPacira BioSciences Inc.
News · 26 weeks71-30%
2025-10-262026-04-19
Mix4090d
- Insider17(43%)
- Other12(30%)
- SEC Filings7(18%)
- Earnings3(8%)
- Leadership1(3%)
Latest news
25 items- INSIDERSEC Form 4 filed by Cross Shawn4 - Pacira BioSciences, Inc. (0001396814) (Issuer)
- SECSEC Form PREC14A filed by Pacira BioSciences Inc.PREC14A - Pacira BioSciences, Inc. (0001396814) (Subject)
- PRPacira to Report First Quarter 2026 Financial Results on Thursday April 30, 2026BRISBANE, Calif., April 16, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will report its first quarter 2026 financial results after the close of the U.S. markets on Thursday April 30, 2026. Following the release, the company will host a live conference call and webcast at 4:30 p.m. ET. For listeners who wish to participate in the question and answer session via telephone, please pre-register here. All registrants will receive dial-in information and a PIN allowing them to access the live call. In addition, a live audio of th
- PRPacira Presents Real-World Data on EXPAREL® Showing Lower Total Healthcare Costs in Outpatient Total Hip and Knee Arthroplasty Procedures-- Select findings demonstrate that the use of EXPAREL® (bupivacaine liposome injectable suspension) in outpatient Total Hip Arthroplasty (THA) and Total Knee Arthroplasty (TKA) is associated with lower total healthcare costs over various follow-up periods — -- Reduced opioid use observed at 6 months post-surgery among Medicare Advantage patients with low back pain in THA Study -- BRISBANE, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today presented data from three real-world studies supporting the economic value of EXPAREL® (b
- SECSEC Form SCHEDULE 13G filed by Pacira BioSciences Inc.SCHEDULE 13G - Pacira BioSciences, Inc. (0001396814) (Subject)
- PRPacira BioSciences to Participate in Fireside Chat at the 25th Annual Needham Virtual Healthcare ConferenceBRISBANE, Calif., April 08, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will participate in an analyst-led fireside chat at the 25th Annual Needham Virtual Healthcare Conference at 9:30 AM ET on Wednesday, April 15, 2026. Live audio of the virtual event can be accessed by visiting the "Events" page of the company's website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event. Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Pacira today announced the granting of indu
- PRPacira BioSciences to Present Real-World Data on EXPAREL® Showing Reduced Cost of Care at Orthopaedic Research Society 2026 Annual Meeting-- Studies highlight reduced total cost of care and select healthcare resource utilization outcomes in total knee arthroplasty (TKA) and spinal fusion -- BRISBANE, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced findings from two real-world studies evaluating the economic benefits of EXPAREL® (bupivacaine liposome injectable suspension) in orthopaedic procedures, including total knee arthroplasty (TKA) and spinal fusion. In both studies, EXPAREL was associated with lower total cost of care compared with ropivacaine in
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Pacira BioSciences Inc.SCHEDULE 13G/A - Pacira BioSciences, Inc. (0001396814) (Subject)
- INSIDERAmendment: SEC Form 4 filed by Kronenfeld Mark A.4/A - Pacira BioSciences, Inc. (0001396814) (Issuer)
- INSIDERSEC Form 4 filed by Slonin Jonathan4 - Pacira BioSciences, Inc. (0001396814) (Issuer)
- INSIDERSEC Form 4 filed by Froimson Mark4 - Pacira BioSciences, Inc. (0001396814) (Issuer)
- SECSEC Form DEFA14A filed by Pacira BioSciences Inc.DEFA14A - Pacira BioSciences, Inc. (0001396814) (Filer)
- PRPacira BioSciences Reaffirms Commitment to Shareholder Value Creation-- Issues Statement in Response to DOMA's Nomination of Director Candidates -- -- No Shareholder Action Required at This Time -- BRISBANE, Calif., March 11, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today confirmed that DOMA Perpetual Capital Management LLC ("DOMA") has nominated three director candidates to stand for election to the Pacira Board of Directors (the "Board") at the Company's 2026 Annual Meeting of Stockholders (the "2026 Annual Meeting"). Pacira's Board issued the following statement: The Pacira Board of Directors and managemen
- PRDOMA Perpetual Nominates Three Highly Qualified Candidates for the Board of Pacira BioSciences, Inc.Pacira's Stock is Down 56% Over the Last Decade and Down 68% Over the Last 5 Yearsi; Under the Leadership of CEO and Board Member Frank Lee, the Stock Has Fallen 30%ii; The Company's Underperformance is Reflected in Consistently Missed Earnings, Continuous Lowering of Guidance, Which is Then Missed, and a Complete Lack of Combined Profitability in the Last Two Yearsiii; We believe the Stock Price Reflects the Market's Lack of Trust in Management and the Board of Director's Utter Failure of OversightDOMA Asserts Frank Lee Should be Replaced Immediately; the Board Should Name an Interim CEO and Conduct a Formal Sale Process of the Business DOMA's Three Highly Qualified Nominees Possess Vast Ex
- PRPacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BRISBANE, Calif., March 06, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on March 3, 2026 to three new employees under Pacira's Amended and Restated 2014 Inducement Plan (the "Inducement Plan") as a material inducement to each employee's entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), the awards were approved by the People & Compensation Committee of the Board of Directors (the "Committee") without stockholder approval. One employee received stock options to purchase
- PRPacira BioSciences to Participate in Fireside Chat at the Barclays 28th Annual Global Healthcare ConferenceBRISBANE, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will participate in an analyst-led fireside chat at the Barclays 28th Annual Global Healthcare Conference at 2:30 PM ET on Wednesday, March 11, 2026 in Miami. Live audio of the event can be accessed by visiting the "Events" page of the company's website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event. About PaciraPacira delivers innovative, non-opioid pain therapies to transform the lives of patie
- PRPacira BioSciences Presents Two Real-World Studies from Its Innovations in Genicular Outcomes Registry (IGOR)-- Studies highlight the clinical effectiveness of EXPAREL for total knee arthroplasty and long-term pain management with ioveraº for patients with osteoarthritis (OA) of the knee -- -- Data presented at the American Academy of Orthopedic Surgeons 2026 Annual Meeting -- BRISBANE, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today presented real-world evidence from its Innovations in Genicular Outcomes Registry, (IGOR), a first-of-its-kind multicenter, prospective, longitudinal observational registry. The first study demonstra
- SECSEC Form S-8 filed by Pacira BioSciences Inc.S-8 - Pacira BioSciences, Inc. (0001396814) (Filer)
- SECSEC Form 10-K filed by Pacira BioSciences Inc.10-K - Pacira BioSciences, Inc. (0001396814) (Filer)
- SECPacira BioSciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Pacira BioSciences, Inc. (0001396814) (Filer)
- PRPacira BioSciences Reports Fourth Quarter and Full-Year 2025 Financial Results— Record-high EXPAREL sales driven by volume growth of 7 percent, marking strongest fourth quarter performance in three years — — Conference call today at 4:30 p.m. ET — BRISBANE, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today reported financial results for the fourth quarter and full-year of 2025. "2025 was a year of disciplined execution for Pacira. With the launch of our 5x30 strategy, we reignited momentum across the business and delivered strong, measurable progress. Our products benefitted more than 2.5 million patients
- INSIDERChief Administrative Officer Williams Kristen was granted 54,546 shares, increasing direct ownership by 42% to 185,849 units (SEC Form 4)4 - Pacira BioSciences, Inc. (0001396814) (Issuer)
- INSIDERChief Financial Officer Cross Shawn was granted 49,091 shares, increasing direct ownership by 87% to 105,341 units (SEC Form 4)4 - Pacira BioSciences, Inc. (0001396814) (Issuer)
- INSIDERSenior Vice President, Finance Riker Lauren was granted 19,273 shares, increasing direct ownership by 37% to 71,586 units (SEC Form 4)4 - Pacira BioSciences, Inc. (0001396814) (Issuer)
- INSIDERChief Commercial Officer Teehan Brendan was granted 51,714 shares, increasing direct ownership by 105% to 100,934 units (SEC Form 4)4 - Pacira BioSciences, Inc. (0001396814) (Issuer)